MX2010010517A - Antagonistas de receptor de glucagon. - Google Patents

Antagonistas de receptor de glucagon.

Info

Publication number
MX2010010517A
MX2010010517A MX2010010517A MX2010010517A MX2010010517A MX 2010010517 A MX2010010517 A MX 2010010517A MX 2010010517 A MX2010010517 A MX 2010010517A MX 2010010517 A MX2010010517 A MX 2010010517A MX 2010010517 A MX2010010517 A MX 2010010517A
Authority
MX
Mexico
Prior art keywords
seq
fab fragment
fab
fragment
monoclonal antibody
Prior art date
Application number
MX2010010517A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Ihor Korytko
Rohn Lee Millican Jr
Brian John Ondek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010010517(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010010517A publication Critical patent/MX2010010517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010010517A 2008-03-27 2009-03-17 Antagonistas de receptor de glucagon. MX2010010517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27
PCT/US2009/037349 WO2009120530A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010010517A true MX2010010517A (es) 2010-12-20

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010517A MX2010010517A (es) 2008-03-27 2009-03-17 Antagonistas de receptor de glucagon.

Country Status (15)

Country Link
US (2) US7968686B2 (enExample)
EP (1) EP2268670A1 (enExample)
JP (1) JP5438095B2 (enExample)
KR (1) KR101235934B1 (enExample)
CN (1) CN101983208A (enExample)
AR (1) AR070844A1 (enExample)
AU (1) AU2009228866A1 (enExample)
BR (1) BRPI0910118A2 (enExample)
CA (1) CA2719761A1 (enExample)
CL (1) CL2009000586A1 (enExample)
EA (1) EA201071126A1 (enExample)
MX (1) MX2010010517A (enExample)
PE (1) PE20091674A1 (enExample)
TW (1) TW201000126A (enExample)
WO (1) WO2009120530A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012005208A2 (pt) * 2009-09-08 2016-11-22 Neopharm Co Ltd antiocorpos contra o receptor de glucagon e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
WO2014181229A2 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US10626179B2 (en) 2014-06-08 2020-04-21 Remd Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
CN118236497A (zh) 2016-08-30 2024-06-25 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
SG11201906682YA (en) 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3515112B2 (ja) 1992-08-28 2004-04-05 ノボ ノルディスク アクティーゼルスカブ グルカゴン・レセプタ
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
JP5001364B2 (ja) 2006-07-04 2012-08-15 ブラッコ イメージング ソチエタ ペル アチオニ 腫瘍性組織等の生物組織を局部的に熱剥離するための装置
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
CN101983208A (zh) 2011-03-02
US20090252727A1 (en) 2009-10-08
TW201000126A (en) 2010-01-01
BRPI0910118A2 (pt) 2015-12-29
US7968686B2 (en) 2011-06-28
AR070844A1 (es) 2010-05-05
KR20100117130A (ko) 2010-11-02
KR101235934B1 (ko) 2013-02-21
US20110212092A1 (en) 2011-09-01
JP2011518125A (ja) 2011-06-23
EA201071126A1 (ru) 2011-04-29
AU2009228866A1 (en) 2009-10-01
CL2009000586A1 (es) 2010-06-04
JP5438095B2 (ja) 2014-03-12
WO2009120530A1 (en) 2009-10-01
PE20091674A1 (es) 2009-11-04
CA2719761A1 (en) 2009-10-01
EP2268670A1 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
MX2010010517A (es) Antagonistas de receptor de glucagon.
US12202891B2 (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
JP6592059B2 (ja) アルファシヌクレインを認識するヒト化抗体
TWI423818B (zh) Ｃｇｒｐ抗體
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
JP6109571B2 (ja) 複数種のＣＣケモカインと結合するａｎｔｉｋｉｎｅ抗体
KR20200119846A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
MX2011001909A (es) Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos.
JP2023541627A (ja) Ｉｌ１ｒａｐに結合する抗体及びその使用
KR20220030934A (ko) 항-gal9 면역-억제 결합 분자
CN109721656A (zh) 靶向rankl的治疗性抗体
JPWO2017122666A1 (ja) 抗Ｍｙｌ９抗体
CN116368153A (zh) Zip12抗体
TW202442678A (zh) 包含抗-baff抗體的雙特異性結合蛋白及其用途
WO2024094017A1 (zh) 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
RU2779649C1 (ru) Антитело, связывающее человеческий il-4r, его антигенсвязывающий фрагмент и его медицинское применение
WO2025237353A1 (zh) 一种抗gipr抗体或其抗原结合片段及用途
AU2024285833A1 (en) Antibody binding to il-11, antigen-binding fragment thereof, and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal